3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
68
Carboplatin
64
pembrolizumab
32
Cyclophosphamide
31
Bevacizumab
27
liposomal doxorubicin
24
Cisplatin
24
Topotecan
21
Gemcitabine
21
olaparib
18
fludarabine
16
Taxes
16
Docetaxel
15
Nivolumab
14
Doxorubicin
14
niraparib
13
veliparib
12
Albumin-Bound Paclitaxel
11
aldesleukin
9
Filgrastim
9
fludarabine phosphate
8
durvalumab
8
Oxaliplatin
8
Fluorouracil
8
Drug Therapy
8
sargramostim
7
Peripheral Blood Stem Cell Transplantation
7
Magnetic Resonance Spectroscopy
7
Leucovorin
7
talazoparib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Ovarian Neoplasms
×
AM0010
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled